Reach Us +44-1647-403003
In vivo Quantification of Abasic Sites for Efficacious Evaluation of DNA Targeted Chemotherapies | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

In vivo Quantification of Abasic Sites for Efficacious Evaluation of DNA Targeted Chemotherapies

Wenxia Zhu, Chunying Wu, Yuguo Li, Eduardo Somoza, Lili Liu, Stanton Gerson and Yanming Wang*

Division of Radiopharmaceutical Science, Case Center for Imaging Research, Department of Radiology, Case Western Reserve University, Cleveland, OH 44106

*Corresponding Author:
Yanming Wang, PhD
Division of Radiopharmaceutical Science
Case Center for Imaging Research
Department of Radiology
Case Western Reserve University
Cleveland, OH 44106, USA
Tel: 216 844 3288
Fax: 216 844 8062
E-mail: [email protected]

Received Date: January 03, 2012; Accepted Date: February 22, 2012; Published Date: February 24, 2012

Citation: Zhu W, Wu C, Li Y, Somoza E, Liu L, et al. (2012) In vivo Quantification of Abasic Sites for Efficacious Evaluation of DNA-Targeted Chemotherapies. J Cancer Sci Ther S5:006. doi:10.4172/1948-5956.S5-006

Copyright: © 2012 Zhu W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


DNA damage and repair represent important biological processes that are targets of various chemotherapies against cancer. In many ways, chemotherapeutic agents can induce DNA damage in cancerous as well as normal cells. However, DNA damage induced by chemotherapeutic agents can be intrinsically repaired by normal physiologic responses, which hampers inhibition of tumor growth and cause drug-resistance. Base excision repair (BER) is one such physiologic process that is important in the cellular response to many chemotherapeutic agents, specifically those agents that target DNAs. Once the BER pathway is triggered, damaged DNA bases undergo a series of chemical modifications resulting in the formation of abasic or apurinic/apyrimidinic (AP) site, which serves as key intermediates in the excision of damaged DNA bases and restoration of regular bases. To monitor BER- conferred intrinsic drug-resistance to chemotherapeutic agents such as DNA-alternating temozolomide (TMZ), pemetrexed (Alimta ® ), and fludarabine, we have developed a F-18 labeled fluoroethoxyamine ([ 11 C]FEX) as an imaging agent for positron emission tomography (PET) imaging of DNA damage and repair in vivo . In this work, we report the synthesis, radiolabeling, and evaluation of [ 18 F]FEX in vivo in mice. We have shown that [ 18 F]FEX- PET can be used to monitor DNA damage and repair in tumor xenograft mouse models including an uracil DNA glycosylase (UDG)-knockout tumor mouse model of non-small cell lung cancer (NSCLC).

Share This Page